Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM EBITDA Multiple | 128,5x - 142,1x | 135,3x |
Selected Fwd EBITDA Multiple | 16,9x - 18,7x | 17,8x |
Fair Value | $7,38 - $7,83 | $7,60 |
Upside | -30,3% - -26,0% | -28,1% |
Benchmarks | Ticker | Full Ticker |
Novavax, Inc. | NVAX | NasdaqGS:NVAX |
Moderna, Inc. | MRNA | NasdaqGS:MRNA |
Gilead Sciences, Inc. | GILD | NasdaqGS:GILD |
BioNTech SE | BNTX | NasdaqGS:BNTX |
Pfizer Inc. | PFE | NYSE:PFE |
Dynavax Technologies Corporation | DVAX | NasdaqGS:DVAX |
- | - | - |
Select LTM EBITDA Multiple | |||||||
Benchmark Companies | |||||||
NVAX | MRNA | GILD | BNTX | PFE | DVAX | ||
NasdaqGS:NVAX | NasdaqGS:MRNA | NasdaqGS:GILD | NasdaqGS:BNTX | NYSE:PFE | NasdaqGS:DVAX | ||
Historical EBITDA Growth | |||||||
5Y CAGR | NM- | NM- | 4.6% | NM- | 11.0% | NM- | |
3Y CAGR | NM- | NM- | -1.3% | NM- | -10.1% | -66.4% | |
Latest Twelve Months | 240.0% | 22.4% | 13.0% | -519.2% | 38.2% | 121.1% | |
Historical EBITDA Profit Margin | |||||||
5 Year Average Margin | -67.9% | -39.2% | 48.2% | 11.9% | 35.5% | -15.5% | |
Prior Fiscal Year | -51.9% | -52.8% | 44.1% | 29.1% | 31.5% | -11.2% | |
Latest Fiscal Year | -26.9% | -116.1% | 46.8% | -37.6% | 36.7% | 2.0% | |
Latest Twelve Months | 37.3% | -111.3% | 47.8% | -37.1% | 37.3% | 1.2% | |
Current Trading Multiples | |||||||
EV / LTM Revenue | 0.48x | 1.69x | 5.31x | 3.18x | 3.03x | 3.05x | |
EV / LTM EBITDA | 1.3x | -1.5x | 11.1x | -8.6x | 8.1x | 254.4x | |
EV / LTM EBIT | 1.4x | -1.4x | 13.9x | -6.8x | 11.5x | -788.1x | |
Low | Mid | High | |||||
Benchmark EV / LTM EBITDA | -8.6x | 1.3x | 11.1x | ||||
Historical EV / LTM EBITDA | -720.4x | 3.3x | 32.9x | ||||
Selected EV / LTM EBITDA | 128.5x | 135.3x | 142.1x | ||||
(x) LTM EBITDA | 4 | 4 | 4 | ||||
(=) Implied Enterprise Value | 454 | 478 | 502 | ||||
(-) Non-shareholder Claims * | 371 | 371 | 371 | ||||
(=) Equity Value | 826 | 849 | 873 | ||||
(/) Shares Outstanding | 120.1 | 120.1 | 120.1 | ||||
Implied Value Range | 6.88 | 7.07 | 7.27 | ||||
FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
Implied Value Range (Trading Cur) | 6.88 | 7.07 | 7.27 | 10.58 | |||
Upside / (Downside) | -35.0% | -33.1% | -31.3% |
Equity Waterfall | |||||||
Benchmark Companies | |||||||
(in millions) | NVAX | MRNA | GILD | BNTX | PFE | DVAX | |
Enterprise Value | 605 | 5,356 | 151,857 | 7,681 | 189,290 | 899 | |
(+) Cash & Short Term Investments | 731 | 5,975 | 8,711 | 14,110 | 17,319 | 661 | |
(+) Investments & Other | 0 | 2,424 | 684 | 2,286 | 1,917 | 0 | |
(-) Debt | (229) | (745) | (24,952) | (293) | (62,397) | (290) | |
(-) Other Liabilities | 0 | 0 | 84 | 0 | (299) | 0 | |
(-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
(-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
Value of Common Equity | 1,108 | 13,010 | 136,384 | 23,784 | 145,830 | 1,270 | |
(/) Shares Outstanding | 162.0 | 386.7 | 1,243.9 | 246.2 | 5,685.4 | 120.1 | |
Implied Stock Price | 6.84 | 33.64 | 109.64 | 96.59 | 25.65 | 10.58 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 0.86 | 1.00 | 1.00 | |
Implied Stock Price (Trading Cur) | 6.84 | 33.64 | 109.64 | 112.89 | 25.65 | 10.58 | |
Trading Currency | USD | USD | USD | USD | USD | USD | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 0.86 | 1.00 | 1.00 |